Literature DB >> 8609072

Reduced activity of anabolizing enzymes in 5-fluorouracil-resistant human stomach cancer cells.

M Inaba1, J Mitsuhashi, H Sawada, N Miike, Y Naoe, A Daimon, K Koizumi, H Tsujimoto, M Fukushima.   

Abstract

The mechanism of resistance to 5-fluorourcil (5-FU) was studied with NUGC-3/5FU/L, a human stomach cancer cell line which had acquired resistance as a consequence of repeated 5-day exposures to stepwise-increasing concentrations of 5-FU in vitro. NUGC-3/5FU/L was 200-fold and over 16-fold resistant to 96-h and 1-h exposures to 5-FU, respectively. NUGC-3/5FU/L incorporated less 5-FU into RNA, indicating resistance to the RNA-directed action of 5-FU. On the other hand, NUGC-3/5/5FU/L also showed resistance to in situ thymidylate synthase (TS) inhibition by 5-FU. Polymerase chain reaction-single-strand conformation polymorphism analysis of TS cDNA and a FdUMP ligand binding assay showed that quantitative and qualitative alterations of TS are not responsible for this resistance. In contrast, the ability to metabolize 5-FU to its active metabolites, FUTP and FdUMP, was reduced in NUGC-3/5FU/L. We found that not only the activities of uridine phosphorylase/kinase and orotate phosphoribosyl-transferase (OPRT), but also the level of phosphoribosyl pyrophosphate, a cosubstrate for OPRT, were significantly lower in NUGC-3/5FU/L than in the parent NUGC-3. These results indicated that resistance to 5-FU in NUGC-3/5FU/L is due to reduced activities of 5-FU-anabolizing enzymes, but not to an alteration of TS. 2'-Deoxyinosine effectively enhanced TS inhibition by 5-FU in the resistant cells, thus markedly sensitizing them to 5-FU.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8609072      PMCID: PMC5921054          DOI: 10.1111/j.1349-7006.1996.tb03161.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


5‐fluorouracil 5‐fluoro‐2′‐deoxyuridine 5‐fluorouridine 5‐fluoro‐2′‐deoxyuridylate 5‐fluorouridylate 5‐fluorouridine‐5′‐triphosphate 2′‐deoxyuridine 2′‐deoxyinosine ribose‐1‐phosphate 2′‐deoxyribose‐1‐phosphate 5‐phosphoribosyl‐1‐pyrophosphate 10‐CH2‐FH4, 5, 10‐methylene‐tetrahydrofolate Ca++, Mg++‐free phosphate‐buffered saline sulforhodamine B orotate phosphoribosyltransferase thymidylate synthase high‐performance liquid chromatography acid guanidinium thiocyanatephenolchloroform method complementary DNA polymerase chain reaction single‐strand conformation polymorphism polyacrylamide gel electrophoresis
  32 in total

1.  Relationship between 5-fluoro-2'-deoxyuridylate, 2'-deoxyuridylate, and thymidylate synthase activity subsequent to 5-fluorouracil administration, in xenografts of human colon adenocarcinomas.

Authors:  J A Houghton; K D Weiss; L G Williams; P M Torrance; P J Houghton
Journal:  Biochem Pharmacol       Date:  1986-04-15       Impact factor: 5.858

Review 2.  Metabolism and mechanism of action of 5-fluorouracil.

Authors:  W B Parker; Y C Cheng
Journal:  Pharmacol Ther       Date:  1990       Impact factor: 12.310

3.  Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5'-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes.

Authors:  G J Peters; E Laurensse; A Leyva; J Lankelma; H M Pinedo
Journal:  Cancer Res       Date:  1986-01       Impact factor: 12.701

4.  Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules.

Authors:  C Aschele; A Sobrero; M A Faderan; J R Bertino
Journal:  Cancer Res       Date:  1992-04-01       Impact factor: 12.701

5.  Rapid determination of thymidylate synthase activity and its inhibition in intact L1210 leukemia cells in vitro.

Authors:  J C Yalowich; T I Kalman
Journal:  Biochem Pharmacol       Date:  1985-07-01       Impact factor: 5.858

6.  Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil.

Authors:  C P Spears; B G Gustavsson; M Berne; R Frösing; L Bernstein; A A Hayes
Journal:  Cancer Res       Date:  1988-10-15       Impact factor: 12.701

7.  Thymidylate synthase as a determinant of 5-fluoro-2'-deoxyuridine response in human colonic tumor cell lines.

Authors:  S H Berger; F G Berger
Journal:  Mol Pharmacol       Date:  1988-10       Impact factor: 4.436

8.  Variation in human thymidylate synthase is associated with resistance to 5-fluoro-2'-deoxyuridine.

Authors:  S T Davis; S H Berger
Journal:  Mol Pharmacol       Date:  1993-05       Impact factor: 4.436

9.  Flow cytometric analysis of cell-killing actions of 5-fluorouracil in human colorectal cancer cells.

Authors:  M Inaba; J Mitsuhashi
Journal:  Oncol Res       Date:  1994       Impact factor: 5.574

10.  Alteration of fluorouracil metabolism in human colon cancer cells by dipyridamole with a selective increase in fluorodeoxyuridine monophosphate levels.

Authors:  J L Grem; P H Fischer
Journal:  Cancer Res       Date:  1986-12       Impact factor: 12.701

View more
  13 in total

Review 1.  TAS-102, a novel antitumor agent: a review of the mechanism of action.

Authors:  Heinz-Josef Lenz; Sebastian Stintzing; Fotios Loupakis
Journal:  Cancer Treat Rev       Date:  2015-06-06       Impact factor: 12.111

2.  Development of stealth liposome formulation of 2'-deoxyinosine as 5-fluorouracil modulator: in vitro and in vivo study.

Authors:  Raphaelle Fanciullino; Sarah Giacometti; Claude Aubert; Frederic Fina; Pierre-Marie Martin; Philippe Piccerelle; Joseph Ciccolini
Journal:  Pharm Res       Date:  2005-10-21       Impact factor: 4.200

3.  Removal of antineoplastic drugs cyclophosphamide, ifosfamide, and 5-fluorouracil and a vasodilator drug pentoxifylline from wastewaters by ozonation.

Authors:  Angela Yu-Chen Lin; Julia Han-Fang Hsueh; P K Andy Hong
Journal:  Environ Sci Pollut Res Int       Date:  2014-08-05       Impact factor: 4.223

4.  Orotate phosphoribosyl transferase mRNA expression and the response of cholangiocarcinoma to 5-fluorouracil.

Authors:  Chariya Hahnvajanawong; Jariya Chaiyagool; Wunchana Seubwai; Vajarabhongsa Bhudhisawasdi; Nisana Namwat; Narong Khuntikeo; Banchob Sripa; Ake Pugkhem; Wichittra Tassaneeyakul
Journal:  World J Gastroenterol       Date:  2012-08-14       Impact factor: 5.742

5.  Synergistic antitumor effect of combined 5-fluorouracil (5-FU) with 5-chloro-2,4-dihydroxypyridine on 5-FU-resistant gastric cancer cells: possible role of a dihydropyrimidine dehydrogenase-independent mechanism.

Authors:  Eiji Sasaki; Kazunari Tominaga; Hikaru Kuwamura; Toshio Watanabe; Yasuhiro Fujiwara; Nobuhide Oshitani; Kazuhide Higuchi; Tetsuo Arakawa
Journal:  J Gastroenterol       Date:  2007-10-15       Impact factor: 7.527

6.  Role of thymidine phosphorylase and orotate phosphoribosyltransferase mRNA expression and its ratio to dihydropyrimidine dehydrogenase in the prognosis and clinicopathological features of patients with pancreatic cancer.

Authors:  Kotaro Miyake; Satoru Imura; Tomoharu Yoshizumi; Tetsuya Ikemoto; Yuji Morine; Mitsuo Shimada
Journal:  Int J Clin Oncol       Date:  2007-04-27       Impact factor: 3.402

Review 7.  Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies.

Authors:  Godefridus J Peters
Journal:  Ther Adv Med Oncol       Date:  2015-11       Impact factor: 8.168

8.  Overexpression of the orotate phosphoribosyl-transferase gene enhances the effect of 5-Fluorouracil in head and neck squamous cell carcinoma in vitro.

Authors:  Ryuji Yasumatsu; Torahiko Nakashima; Shizuo Komune
Journal:  J Oncol       Date:  2012-03-26       Impact factor: 4.375

9.  Trifluridine/tipiracil overcomes the resistance of human gastric 5-fluorouracil-refractory cells with high thymidylate synthase expression.

Authors:  Kazuaki Matsuoka; Fumio Nakagawa; Takashi Kobunai; Teiji Takechi
Journal:  Oncotarget       Date:  2018-02-05

10.  Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer.

Authors:  W Ichikawa; H Uetake; Y Shirota; H Yamada; T Takahashi; Z Nihei; K Sugihara; Y Sasaki; R Hirayama
Journal:  Br J Cancer       Date:  2003-10-20       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.